IGM Biosciences — Investor Presentation (January 2023)
37 slides from IGM Biosciences's investor presentation, Jan 6, 2023
Slide 1: Corporate Overview: Global Leaders in IgM Antibodies
Corporate Overview January 6, 2023 Global Leaders in IgM Antibodies Exhibit 99.1 Igm biosciences® REIMAGINING antibody medicines
Slide 2: Forward-looking statements
Forward-looking statements . This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current views of the management of IGM Biosciences, Inc. (the “Company,” “we” or “our”) based
Slide 3: Global leaders in engineering and manufacturing IgM antibodies
Global leaders in engineering and manufacturing IgM antibodies IgM antibodies have structural attributes that provide advantages relative to traditional IgG antibodies in multiple applications Agonist antibodies T cell engaging antibodies Targeted cytokine delivery We plan to extend our global leade
Slide 4: IgM antibodies have unique structural attributes compared to IgG antibodies
Additional binding sites lead to: Superior total binding power (avidity) Increased cross-linking of receptors for greater agonism IgM antibodies have unique structural attributes compared to IgG antibodies IgG IgM 2 BINDING SITES 10 BINDING SITES J-Chain allows for novel bi-specifics IgM core can en
Slide 5: Strategic priorities for 2023
Strategic priorities for 2023 Accelerate development of our agonist Death Receptor 5 IgM antibody (IGM-8444) Develop our IgM T cell engager antibodies in autoimmune disease Extend our clinical pipeline Continue to develop our IgM antibody platform Igm biosciences® 5
Slide 6: Strong DR5 activation requires multi-receptor agonism
Strong DR5 activation requires multi-receptor agonism DR5 is highly expressed across many different tumor types In vitro apoptosis comparing IgG and IgM DR5 antibodies using the same binding domain IgG IgM Ligand Apoptosis Cell Death Weak Apoptosis Cell Death Strong Apoptosis Cell Death [BAR_CHART]I
Slide 7: IGM-8444: activity seen in combination with irinotecan (in vivo)
IGM-8444 (5 mg/kg Q2D x 7) Irinotecan (100 mg/kg QW x 3) IGM-8444: activity seen in combination with irinotecan (in vivo) One of the active agents in FOLFIRI chemotherapy treatment [BAR_CHART] Igm biosciences® 7
Slide 8: IGM-8444: encouraging clinical safety profile in FOLFIRI combination
IGM-8444: encouraging clinical safety profile in FOLFIRI combination Treatment-emergent adverse events in FOLFIRI combination cohorts fatigue IRR vomiting nausea 20% diarrhea 20% AST inc. Bili inc. 28 total patients treated with IGM-8444 + FOLFIRI DLTs: None SAEs: 8 patients - all unrelated Grade 3+
Slide 9: IGM-8444: Encouraging efficacy profile in colorectal cancer combination
IGM-8444: Encouraging efficacy profile in colorectal cancer (CRC) combination. Strong rationale for randomized CRC study with FOLFIRI 9 All CRC patients treated in second through fourth FOLFIRI combo cohorts who are time eligible for second scan by data cut-off Best percentage change in tumor size P
Slide 10: Selected patient profiles: substantial benefit in refractory patients
Selected patient profiles: substantial benefit observed in patient's refractory to prior FOLFOX/FOLFIRI treatment Data cut-off: December 31, 2022 *Response Confirmed 69, mCRC, MSS, KRASmt, BRAFwt Prior FOLFIRI progression Prior Treatments Time on Tx Outcome Xeloda 5m FOLFIRI + bev 5m SD PD XELOX 2
Slide 11: Randomized second line metastatic colorectal cancer trial
Randomized second line metastatic colorectal cancer trial Expected initiation: Q1 2023 11 FOLFIRI + bevacizumab n=80 1:1 Randomization IGM-8444 at 3 mg/kg + FOLFIRI + bevacizumab R Crossover allowed at PD IGM-8444 at 3 mg/kg + FOLFIRI + bevacizumab PD Population Global Trial 2L CRC Prior FOLFIRI exc
Slide 12: Initial focus of IGM-8444 development: improving FOLFIRI + bevacizumab
Initial focus of IGM-8444 development: improving FOLFIRI + bevacizumab, the most common regimen for 2L colorectal cancer 1L 2L 3L+ Current Standard of Care FOLFOX (or other 5-FU chemo combos) + targeted agents FOLFIRI (or other 5-FU chemo combos) ± targeted agents Various Current Standard of Care Be
Slide 13: Synergistic activity with venetoclax and birinapant (in vivo)
Synergistic activity seen in combination with other apoptotic pathway drugs: venetoclax and birinapant (in vivo) Triple Negative Breast Cancer Model (MDA-MB-231) Source: Sinclair, A. "Multimeric IgM antibodies targeting DR5 are potent and rapid inducers of tumor cell apoptosis In Vitro and In Vivo"
Slide 14: Additional IGM-8444 ongoing combination studies
Additional IGM-8444 ongoing combination studies Data cut-off: December 16, 2022 Additional Combination Cohorts IGM-8444 + Birinapant IGM-8444 + Venetoclax Planned Activities 4th dose cohort currently being tested No DLTs observed Solid tumors, all comers 1st cohort open in SLL/CLL 1st cohort open in
Slide 15: Strategic priorities for 2023
Strategic priorities for 2023 Accelerate development of our agonist Death Receptor 5 IgM antibody (IGM-8444) Develop our IgM T cell engager antibodies in autoimmune disease Extend our clinical pipeline Continue to develop our IgM antibody platform Igm biosciences® 15
Slide 16: Using T cells to treat autoimmune disease via deep B cell depletion
Using T cells to treat autoimmune disease via deep B cell depletion Recent proof of concept data showed extensive B cell depletion using an anti-CD19 CAR-T can treat autoimmune patients and potentially reset their immune systems 5 patients with treatment refractory systemic lupus erythematosus (SLE)
Slide 17: T cell engagement with imvotamab can enable deep B cell depletion
T cell engagement with imvotamab can enable deep B cell depletion Imvotamab non-human primate cross reactive surrogate achieves >85% reduction of CD20+ B cells in spleen, mesenteric lymph nodes and bone marrow Deep depletion of CD20+ cells within tissue (in vivo) More effective depletion of low CD20
Slide 18: Opportunity for IgM T cell engager antibodies in autoimmune disease
Opportunity for IgM T cell engager antibodies in autoimmune disease CD20 targeted antibodies are used with varying degrees of success in a broad range of autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis Monospecific anti-CD20 antibodies d
Slide 19: Strategic priorities for 2023
Strategic priorities for 2023 Accelerate development of our agonist Death Receptor 5 IgM antibody (IGM-8444) Develop our IgM T cell engager antibodies in autoimmune disease Extend our clinical pipeline Continue to develop our IgM antibody platform Igm biosciences® 19
Slide 20: Imvotamab oncology clinical development
Imvotamab oncology clinical development Arm A: 15/50/100 mg titration dose Arm B: 15/50/100/300mg titration dose Monotherapy dose finding studies Potential combination studies * Combination will start with a full dose of loncastuximab with 100 mg of imvotamab R imvotamab + loncastuximab R/R NHL* Dos
Slide 21: Imvotamab plus loncastuximab: increased potency (in vivo)
Imvotamab plus loncastuximab: increased potency (in vivo) Two tumor targets, two mechanisms of action: reduced chance for escape % Tumor growth inhibition Efficacy model is Raji s.c. with human PBMC engraftment 5 mg/kg imvotamab q2dx12 i.v. starting on day 5 0.1 mg/kg loncastuximab is a single i.p.
Slide 22: IGM-7354: Targeted IL-15 delivery via PD-L1 expressing cells
IGM-7354: Targeted IL-15 delivery via PD-L1 expressing cells NK or CD8 T cell expansion IGM - 7354 IGM-7354 presents IL-15 to CD8 and NK cells Targeted delivery may increase efficacy and reduce toxicity First patient dosing expected: Q1, 2023 Tumor and/or Antigen Presenting Cell IL-15/IL-15R x anti-
Slide 23: Immune stimulation with IGM-7354
Immune stimulation with IGM-7354 Adapted from Giffon et al., AACR 2022 1 mg/kg Vehicle 3 mg/kg 10 mg/kg 1 mg/kg Vehicle 3 mg/kg 10 mg/kg (in vivo) (in vivo) [BAR_CHART] Igm biosciences® 23
Slide 24: Expansion of T Cell engager platform beyond imvotamab
Expansion of T Cell engager platform beyond imvotamab IGM-2644 CD38 x CD3 Multiple Myeloma Autoimmunity Multiple Myeloma Phase 1 study initiation expected Q1 2023 Indications Timing IGM-2537 CD123 x CD3 AML MDS ALL AML Phase 1 study initiation expected H2 2023 Igm biosciences® 24
Slide 25: IGM-2644 (CD38 x CD3) shows robust activity in pre-clinical models
IGM-2644 (CD38 x CD3) shows robust activity in pre-clinical models Differentiated potency against low CD38 expression cells (in vitro) CD38 expression level [BAR_CHART] Igm biosciences® 25
Slide 26: IGM-2644: reduced cytokine release relative to bispecific IgG
IGM-2644: reduced cytokine release relative to bispecific IgG (in vitro) Bispecific IgG IGM-2644 IGM-2644 IGM-2644 IGM-2644 Bispecific IgG Bispecific IgG Bispecific IgG [BAR_CHART] Igm biosciences® 26
Slide 27: IGM-2537 (CD123 x CD3): Robust activity in AML model
IGM-2537 (CD123 x CD3): Robust activity in acute myeloid leukemia model (in vivo) MV4-11 AML Xenograft Model [BAR_CHART] Igm biosciences® 27
Slide 28: IGM-2537: Reduced cytokine release relative to bispecific IgG
IGM-2537: Reduced cytokine release relative to bispecific IgG (in vitro) Bispecific IgG Bispecific IgG MV4-11: IL-2 release MV4-11: IL-4 release MV4-11: IFNγ release Reduced cytokine release compared to bispecific IgG [BAR_CHART] Igm biosciences® 28
Slide 29: Strategic priorities for 2023
Strategic priorities for 2023 Accelerate development of our agonist Death Receptor 5 IgM antibody (IGM-8444) Develop our IgM T cell engager antibodies in autoimmune disease Extend our clinical pipeline Continue to develop our IgM antibody platform Igm biosciences® 29
Slide 30: Next Generation: Co-stimulatory IgM T cell engagers
Next Generation: Co-stimulatory IgM T cell engagers Two activation signals within single immune synapse Enhanced T cell activation CD28 or 41BBL co-stimulation provides increased T cell activation and proliferation for sustained anti-tumor response IgM platform allows dual-engagement while maintaini
Slide 31: T cell co-stimulation can create significantly enhanced T cell activation
T cell co-stimulation can create significantly enhanced T cell activation (in vitro) Signal 1+2 Signal 1 Signal 2 CD28 co-stimulation with CD3 (T-cell activation) 4-1BBL co-stimulation with CD3 (T-cell Activation)* *T cell activation uses a 4-1BB expressing reporter cell activation assay [BAR_CHART]
Slide 32: Novel therapeutic approaches to address infectious diseases
Novel therapeutic approaches to address infectious diseases IgMs evolutionarily designed as “the first line of humoral defense” Opportunities to maximize therapeutic potential Differentiated applications in infectious diseases “Virus trapping” antivirals Aerosolized/inhaled therapeutics Affinity eng
Slide 33: Viral trapping strategy using IgM structure and avidity
Viral trapping strategy: IgM structure/avidity enables virus neutralization by “trapping” the virus using its cellular receptor IgM core Molecular construction ACE2 receptor (cellular receptor for SARS viruses) ACE2-decamer ACE2-decamer is ~100x more potent than bivalent ACE2-IgG-Fc in neutralizing
Slide 34: IgM virus trapping is a novel antiviral strategy resilient against viral evolution
IgM virus trapping is a novel antiviral strategy designed to be resilient against viral evolution Antiviral potency of ACE2-decamer designed to be retained despite viral mutations SARS-family viruses may not be able to change dependence on their sole receptor (ACE2) for infection Designed to improve
Slide 35: Sanofi/IGM multi-target collaboration agreement
Sanofi/IGM multi-target collaboration agreement $150M upfront payment received Equity investment in April 2022 follow-on offering Potentially $6B+ in preclinical, clinical, regulatory and commercial milestone payments Sanofi responsible for worldwide commercialization Financial Terms Global research
Slide 36: Multiple catalysts anticipated over next eighteen months
Multiple catalysts anticipated over next eighteen months Clinical Data and Pipeline Expansion Igm biosciences® 36 Clinical Data and Pipeline Expansion IGM-8444 (DR5) Initial randomized IGM-8444 + FOLFIRI + bevacizumab data in 2L colorectal cancer patients Imvotamab (CD20 x CD3) Initial clinical data
Slide 37: Global Leaders in IgM Antibodies
Global Leaders in IgM Antibodies Igm biosciences® REIMAGINING antibody medicines
IGM Biosciences — Investor Presentation (January 2023) on 6ix